COMMUNIQUÉS West-GlobeNewswire

Sienna Announces September Dividend
14/09/2018
MARKHAM, Ontario, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.0765 per common share of the Company (each, a “Common Share”) [...]
Nuvectra® Announces Closing of Follow-On Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
14/09/2018
PLANO, Texas, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today the closing of its underwritten follow-on public offering of 3,248,750 [...]
Major shareholder announcement
14/09/2018
Company Announcement 14 September 2018 Pursuant to section 30 of Consolidated Act no. 12 of 8 January 2018 on capital markets, as amended, NeuroSearch A/S ("NeuroSearch") hereby announces to have received a major [...]
Scythian Biosciences Announces Execution of Share Purchase Agreement with MMJ International Investments Inc., owner of Argentina-based ABP S.A.
14/09/2018
Execution of the Share Purchase Agreement is a Key Benchmark in Finalizing Previously Announced $193 Million Sale of Assets in Caribbean and Latin America Shares to be Received in Consideration for the Proposed Sale of [...]
Free Health Visits, Available Through Teladoc Health, to Residents Impacted by Hurricane Florence
14/09/2018
Residents and Those Displaced Can Call 855-756-8708 to Access Treatment for Non-Emergency Illnesses PURCHASE, NY, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, is [...]
Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pain’s 17th World Congress on Pain
14/09/2018
EVANSTON, Ill., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, [...]
Pieris Pharmaceuticals to Present Preclinical Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the ERS International Congress 2018
14/09/2018
BOSTON, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for [...]
New Lilly Diabetes Center of Excellence Established at the Indiana Biosciences Research Institute
14/09/2018
New center will be a central Indiana nexus for advanced diabetes research and talent attraction INDIANAPOLIS, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) and the Indiana Biosciences Research [...]
European Medicines Agency Validates Marketing Authorization Application for Trogarzo™
14/09/2018
MONTREAL, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that the European Medicines Agency (“EMA”) has confirmed the validity of the marketing [...]
L’Agence européenne des médicaments valide la demande d’autorisation de mise en marché de Trogarzo(MC)
14/09/2018
MONTRÉAL, 14 sept. 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer que l’Agence européenne des médicaments (« AEM ») a confirmé la validité de la demande d’ [...]
VitalHub Corp. Announces Agreement to Acquire Roxy Software Inc. and Option Grants
14/09/2018
TORONTO, Sept. 14, 2018 (GLOBE NEWSWIRE) -- VITALHUB CORP. (TSXV: VHI) (the “Company” or “VitalHub”), is pleased to announce that today it has entered into an agreement (the “Agreement”) to acquire all of the issued and [...]
Summit Therapeutics to Participate in Upcoming Investor Conferences
14/09/2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics to Participate in Upcoming Investor Conferences Oxford, UK, and Cambridge, MA, US, 14 September 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: [...]
Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018
14/09/2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018 Oxford, UK, and Cambridge, MA, US, 14 [...]
IRIDEX Announces Pricing of Public Offering of Common Stock
14/09/2018
MOUNTAIN VIEW, Calif., Sept. 14, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ:IRIX) ("IRIDEX" or the "Company"), an ophthalmic medical technology company focused on the development and commercialization of [...]
Breathtec to Participate in the 2nd Annual RAI$E on the WEST COAST Small-Cap Investing Conference in Vancouver, BC, September 14-15
14/09/2018
VANCOUVER, British Columbia, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH ) (CNSX: BTH ) (FRANKFURT: BTI) (OTCQB: BTHCF ) (the “Company”) will be presenting at the 2nd Annual RAI$E on the WEST [...]
Emblem and Natura Naturals announce termination of letter of intent
14/09/2018
TORONTO, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”) through its wholly-owned subsidiary Emblem Cannabis Corporation, a licensed producer of medical cannabis [...]
Report on Extraordinary General Meeting of NeuroSearch A/S
14/09/2018
Announcement 14 September 2018 At the company’s Extraordinary General Meeting held today, the following resolution was passed: Morten Mathiesen and Mikkel Primdal Kæregaard were elected to the Board of Directors. Karin [...]
PCI Biotech: Rights issue approved by the extraordinary general meeting
14/09/2018
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER [...]
Opthea Presents Phase 1/2a Data of OPT-302 in wet AMD at the Retina Society 2018 Annual Meeting
14/09/2018
MELBOURNE, Australia, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage clinical biopharmaceutical company developing first-in-class novel biologic therapies to treat back-of-the-eye diseases, [...]

Pages